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The triplet excited states of (S)- and (R)-flurbiprofen (FBP) have been used as 
reporters for the microenvironments experienced within the binding sites of human and 
bovine serum albumins. Regression analysis of triplet decay provides valuable 
information on the degree of protection of these excited states from attack by a second 
FBP molecule, oxygen or other reagents. The multiexponential fitting of these decays 
can be satisfactorily correlated with the distribution of the drug among the two binding 
sites and its presence as the non-complexed form in the bulk solution. This assignment 
has been confirmed by using (S)-ibuprofen or caproic acid as selective site-II 
replacement probes. Triplet lifetimes and site occupancy are sensitive to the type of 
serum albumin employed (human vs. bovine). Finally, a low stereodifferentiation has 
been found in the binding behaviour of (S)- and (R)-FBP.  
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Introduction 
Serum albumins (SA) are very abundant proteins in blood and plasma. One of 
their most important physiological roles is to carry a variety of agents (such as fatty 
acids, drugs or metabolites) in the bloodstream to achieve a selective delivery to specific 
targets.1,2 Binding of drugs to SA in biological systems is a key process, as it is relevant 
to modulate a number of properties, including increased solubility in plasma, decreased 
toxicity, protection against oxidation, prolongation of the in vivo half-life, etc. 
Human (HSA) and bovine (BSA) serum albumins have been used as model 
proteins for diverse studies.3,4 They have a well known primary structure and a similar 
folding. Binding of small molecules (i.e. drugs or fatty acids) to HSA and BSA has been 
studied for years through different techniques, in order to understand the functions of 
this unique type of carrier and to disclose the structural basis for designing new 
therapeutic agents.5,6 
Thus, it is known that HSA is synthesised and secreted by liver cells. Its primary 
structure consists of a single chain of 585 amino acid residues containing 17 disulfide 
bridges, one tryptophan (Trp) and one free cysteine; the secondary structure is formed 
by 67% of α helix of six turns, while the three-dimensional structure can be described in 
terms of three domains, each of them constituted in turn by two subdomains.7 Usually, 
drugs bind primarily to high-affinity sites, with typical association constants in the 
range of 104-106 M-1. In addition to the primary sites, lower affinity sites are often 
populated. The pioneering work of Sudlow and coworkers, based on the displacement 
of fluorescence probes, revealed that a great number of drugs bind with high affinity to 
one or two sites, called site I (warfarin binding site) and site II (indole-benzodiazepine 
binding site).8 
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Likewise, BSA is among the most studied and currently used proteins in 
biochemical research; BSA and HSA present 76% sequence identity, but the former 
contains two Trp residues, instead of one. In general, the structural differences observed 
between both albumins are mainly of conservative nature; e. g. hydrophobic amino 
acids are replaced by other hydrophobic amino acids rather than by polar ones. 
Many studies on the drug-protein binding process have used BSA as model, due 
to its similarity to HSA.9,10 However, the binding strength of several ligands (naproxen, 
carprofen and ibuprofen, among others) to the bovine protein has proven to be different 
from that found for the human protein. 11-21 Therefore, the development of new tools for 
the investigation of drug-protein interactions, as well as for the comparison between 
binding of drugs to HSA and BSA, seems to be important in order to integrate the 
existing knowledge.
In the past, a number of techniques (equilibrium dialysis/HPLC, ultrafiltration, 
spectrophotometry, fluorometry, calorimetry, circular dichroism, capillary 
electrophoresis, NMR diffusion measurements, etc) have been used for drug-protein 
binding studies.22-31 Each of them presents advantages and limitations; the latter are 
mainly related to sensitivity, interferences, diffusion problems or lack of reproducibility 
arising from a complicated workup. 
A possible alternative to these methodologies could be based on the detection of 
transients by laser flash photolysis (LFP). Thus, triplet excited states have demonstrated 
to be extremely sensitive to the experienced microenvironment, since their dynamic 
properties can be strongly medium-dependent.32 Hence, these transient species can be 
regarded as potential reporters for the binding of drugs to serum albumins. From the 
multiexponential decay kinetics, it could even be possible to analyse the drug 
distribution among the bulk solution and the different protein binding sites. More 
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interestingly, triplet lifetime measurements would depend on the nature of the drug-
HSA complexes, such as strength of the interaction, conformational restrictions, 
stereochemical requirements, inhibition of self-quenching or triplet-triplet annihilation, 
protection from attack by oxygen or other reagents, etc.  
In a recent preliminary communication, we have reported on the suitability of 
the triplet excited states of (R)- and (S)-flurbiprofen methyl ester (FBPMe) to obtain 
relevant information about the binding of this compound to HSA.33 The triplet lifetimes 
(τT) of (R)- and (S)-FBPMe were dramatically enhanced within the HSA 
microenvironment. Moreover, two different τT values were found for protein-included 
FBPMe, associated with the presence of the drug in two different binding sites. Based 
on these values, the populations of the two binding sites at different [FBPMe]/HSA] 
ratios were determined by regression analysis of the triplet decay traces. 
In our previous work, FPBMe was used for convenience, as its hydrophobic 
character favours inclusion within the protein. However, the analogous information 
obtained from the triplet state of flurbiprofen (FBP, the free carboxilic acid) which is 
the form usually prescribed to patients, would be more relevant for pharmacokinetic 
purposes. 
As shown in Chart I, the non-steroidal anti-inflammatory drug FBP is a 2-
arylpropionic acid. It is prescribed for the relief of mild to moderately severe pain 
accompanied by inflammation (rheumatoid arthritis, osteoarthritis, tendinitis, bursitis) 
and also for ophthalmic disorders. Although the pharmacological effect of FBP is 
mainly due to the (S)-enantiomer, it is usually commercialised as a racemic mixture.34 
Recently, it has been described that FBP inhibits selectively secretion of Aβ42, the most 
toxic component of the senile plaques present in the brain of Alzheimer patients.35 
Concerning the binding to HSA, it has been previously established that FBP binds 
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preferentially to site II, but the lower affinity binding site I is also populated to some 
extent.36,37  
In the present work, we have undertaken a systematic LFP study on both (S)- 
and (R)-FBP in the presence of different amounts of HSA or BSA, using the  well-
characterised triplet-triplet absorption of FBP as reporter.38 It will be shown that the 
most significant differences between both albumins are related to dynamic ranges found 
for the FBP excited state lifetimes within the proteins and to the relative occupancy of 
the two binding sites.  
 
Results and Discussion 
 
(S)-Flurbiprofen/SA systems. 
The behaviour of the (S)-enantiomer of FBP was examined first. For the studies 
in the presence of HSA, a battery of aqueous solutions containing (S)-FBP and HSA 
(molar ratios between 10:1 and 0.3:1) were prepared in neutral buffer (0.01 M PBS) and 
submitted to LFP. In all cases, the transient absorption spectra obtained after laser 
excitation (λexc = 266 nm) displayed a maximum at 360 nm, assigned to the first triplet 
excited state.38 Remarkably, while the decay at 360 nm in the absence of protein 
followed a first order exponential law with a lifetime of 1.5 µs, in the presence of HSA 
it required multiexponential fitting and occurred at longer timescales (Figure 1).  
Thus, when the [(S)-FBP]/[HSA] ratio was between 0.7:1 and 0.5:1, a double 
exponential decay was observed with lifetimes of 11.2 and 35.9 µs. The negligible 
contribution of the 1.5 µs component indicated the absence of free (S)-FBP in solution 
under these conditions. The fact that two different τT values were obtained in the 
presence of HSA correlates well with the existence of two different types of 
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microenvironments (i.e., two different binding sites) in the protein. It is worth 
mentioning that protein-bound (S)-FBP has considerably longer lifetimes (up to 24 
times) than the non-complexed form. This can be attributed to a slower deactivation of 
the excited states inside the HSA binding sites, where an exceptional microenvironment 
protecting the triplet excited state from attack by a second (S)-FBP molecule, oxygen or 
other reagents is provided. In order to check this hypothesis, parallel experiments were 
performed in N2- and O2-purged solutions of (S)-FBP in PBS, both in the absence and in 
the presence of HSA. As a matter of fact, the triplet decay rate increased with increasing 
oxygen concentration. The decay traces are shown in the supporting information (see 
Figures S5 and S6, pp. S11 and S12), while the rate constants are given in Table 1. 
Clearly, the quenching process occurs within the protein microenvironment much 
slower than in the bulk solution. Moreover, protection for oxygen attack seems to be 
more effective within the high affinity Site II. 
  At higher [(S)-FBP]/[HSA] ratios (from 0.8:1 to 10:1), three lifetime values (1.5, 
11.2 and 35.9 µs) were necessary to obtain a good fitting of the decay signal (also 
shown in Figure 1). This can be clearly associated with the presence of the two FBP-
HSA species (τT = 11.2 and 35.9 µs), in addition to free (S)-FBP (τT = 1.5 µs). 
  Regression analysis of the decay curves for [(S)-FBP]/[HSA] ratios from 10:1 to 
0.8:1 allowed to obtain the values of the A1, A2 and A3 coefficients (corresponding to 
the three components with different lifetimes, correlated with free, site I-bound and site 
II-bound FBP). Based on the known fact that the high affinity site of FBP is site II,36,37 
the major component under non-saturating conditions (associated with the longest τT) 
was assigned to FBP within site II; consequently, the minor component (with τT = 11.2 
µs) was assigned to site I-bound FBP. Moreover, in order to obtain independent 
evidence supporting this assignment, additional LFP experiments were performed in the 
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presence of (S)-ibuprofen ((S)-IBP) and capric acid (CA), whose affinity for binding in 
site II is known to be very high.39,40 In good agreement with the initial assumptions, 
addition of IBP or CA to the (S)-FBP/HSA solutions resulted in a reduced contribution 
of the longest lifetime component (site II-bound FBP), with a concomitant enhancement 
of the components assigned to free and site I-bound FBP. The percentages of free, site I- 
and site II-bound FBP in the presence of HSA (and eventually (S)-IBP or CA) are 
shown in Table 2. 
 In order to investigate the behaviour of (S)-FBP in the bovine protein, parallel 
experiments were carried out in the presence of increasing amounts of BSA. Thus, PBS 
solutions of (S)-FBP and BSA (molar ratio in the range from 10:1 to 0.3:1) were 
submitted to LFP. Again, two components with τT = 10.8 and 86.5 µs were obtained for 
the triplet decay (λ = 360 nm) inside the protein. This is shown in Figure 2. 
 Regression analysis of the decay curves for [(S)-FBP]/[BSA] ratios from 10:1 to 
1:1 (where some free drug is present) allowed us to obtain the values of the A1, A2 and 
A3 coefficients. The major component under non-saturating conditions (τT = 86.5 µs) 
was assigned to (S)-FBP in the high affinity binding site (site II), while the minor 
component (with τT = 10.8 µs) was attributed to (S)-FBP within site I. Experiments in 
the presence of (S)-IBP or CA supported this assumption. Relevant data are shown in 
Table 2. 
It is remarkable that the triplet excited state of site II-bound (S)-FBP lived much 
longer (2.4 times) within BSA than within HSA; however, no significant differences 
were found in the corresponding values of site I-bound (S)-FBP. The results indicate 
that the triplet excited state of (S)-FBP is more protected for deactivation (due to attack 
by a second (S)-FBP molecule, oxygen, other reagents, etc.) within the 
microenvironment provided by site II in BSA; besides, binding to this site appears to be 
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the strongest one, as pointed by the fact that replacement of (S)-FBP here is more 
difficult than in the other SA microenviroments. Accordingly, triplet quenching by 
oxygen was slower inside the protein, specially in Site II (see Table 1 and supporting 
information, Figures S5 and S7, pp. S11 and S13). 
 Concerning the site occupancy, as estimated from A coefficients of the  
regression analysis curves, the main differences between the behaviour of the two 
proteins were found at low [(S)-FBP]/[SA] ratios. This is shown in Figure 3; further 
plots illustrating the binding behaviour can be found in the supporting information, 
Figures S10 and S11, pp. S16 and S17. 
(R)- Flurbiprofen/SA systems 
  As stated above, the pharmacological effect or flurbiprofen is mainly attributed 
to the (S)-enantiomer, although the drug is commercialised for therapeutic purposes as a 
racemic mixture. In order to check whether significant differences in the binding 
behaviour were observable for the two enantiomers, a similar study was performed on 
(R)-FBP in the presence of both serum albumins.  
  As expected, in PBS solution the transient absorption spectra and the triplet 
lifetimes of the two FBP enantiomers did not differ from each other. When included 
within HSA, two components with τT 10.2 µs and 39.0 µs were found for (R)-FBP. 
These values were only slightly different from those obtained for (S)-FBP, indicating a 
little stereodifferentiation in the HSA binding process. Representative decays of the 
signal monitored at 360 nm are shown in Figure 4. 
  As in the case of (S)-FBP, LFP experiments for the (R)-FBP/HSA systems in the 
presence of (S)-IBP or CA supported the initial site I and site II assignments. Thus, 
addition of (S)-IBP or CP to the (R)-FBP/HSA solutions resulted in dramatic reduction 
of the amount of site II-bound (R)-FBP (up to 5.8 times lower), with a parallel 
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enhancement of the free and site I-bound species (significant data are shown in Table 
2). 
  Finally, similar studies were carried out for (R)-FBP in the presence of the 
bovine protein. From the LFP kinetic decays of (R)-FBP/BSA solutions (Figure 5), two 
values of τT (6.6 and 58.6 µs) were obtained and attributed to site I-bound and site II-
bound (R)-FBP, respectively. Oxygen quenching experiments led to results similar to 
those obtained with (S)-FBP (Table 1 and supporting information, Figures S8 and S9, 
pp. S14 and S15). 
  On the other hand, addition of (S)-IBP or CA to the (R)-FBP/BSA solutions 
resulted in a redistribution of the bound drug (Table 2), which partially moved from site 
II to site I. Interestingly, no detectable amounts of free drug were found under these 
conditions.  
 The site occupancy, estimated from A coefficients of the regression analysis 
curves, are shown in Figure 6. The main differences between the behaviour of the two 
proteins were found again at low [(S)-FBP]/[SA] ratios. 
  A comparison between the decays monitored at 360 nm for (S)-FBP/HSA (S)-
FBP/BSA, (R)-FBP/HSA and (R)-FBP/BSA is shown in Figure 7. It clearly shows that 
the binding behaviour of FBP is different in the two proteins. Besides, some 
stereodifferentiation occurs in BSA, while no significant differences between the two 




The results obtained in the present work confirm that the triplet drug excited 
states can be used as reporters for the microenvironments experienced within the 
binding sites of transport proteins. Regression analysis of triplet decays can provide 
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valuable information on the degree of protection of these excited states from attack by a 
second drug molecule, oxygen or other reagents. The multiexponential fitting of these 
decays can be satisfactorily correlated with the distribution of the drug among the two 
binding sites and its presence as the non-complexed form in the bulk solution. This 
assignment has been confirmed by using selective site-II replacement probes. Both 
triplet lifetimes and site occupancy are sensitive to the type of serum albumin employed 
(human vs. bovine). Finally, a lower stereodifferentiation has been found in the binding 






HSA and BSA were purchased from Sigma. (S)- and (R)-FBP were obtained 
from Aldrich. 
Absorption spectra 
The absorbance of the solutions was measured in a Perkin Elmer Lambda 35 
UV/Vis Spectrometer. 
Laser flash photolysis experiments.  
Laser flash photolysis experiments were performed by using a Q-switched 
Nd:YAG laser (Quantel Brilliant, 266 nm, 14 mJ per pulse, 5 ns fwhm) coupled to a 
mLFP-111 Luzchem miniaturised equipment. All transient spectra were recorded 
employing 10×10 mm2 quartz cells with 4 mL capacity. The absorbance of FBP was 
found to be ca. 0.2 at the laser wavelength, corresponding to a concentration of 2.5·10-5 
M; concentration of SA was determined using the molar absorption coefficients at 280 
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nm of  35700 M-1cm-1 for HSA and 44720 M-1cm-1 for BSA. All the experiments were 
carried out in PBS (pH = 7.4, 0.01 M) at room temperature (22 ºC) and under air 
atmosphere.  
 For the studies in the presence of SA, a battery of aqueous solutions containing 
(S)- or (R)-FBP and SA (molar ratios between 10:1 and 0.3:1) were prepared in neutral 
buffer (0.01 M PBS) and stored during 15h at 4 ºC to ensure a complete equilibrium 
between the drug and the protein. As an example, the experimental procedure to prepare 
a solution containing FBP and SA in 10:1 molar ratio is briefly described: to 20 mL of a 
2.5·10-5 M solution of (S)- or (R)-FBP in PBS, 25 µL of SA 2·10-3 M in PBS were 
added. The resulting solution (4 mL) was placed in a quartz cuvette and submitted to 
LFP (10 shots for monitoring at 360 nm). To obtain an accurate decay trace, this 
experiment was repeated at least three times with fresh sample; triplet lifetimes and 
fittings of the decay traces were coincident within the experimental error margins. To 
obtain the transient absorption spectra from 700 to 290 nm, fresh sample (drug and 
protein concentración 2.5 10-5 M) was submitted to LFP in a regular interval of 10 nm 
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Figure 1. Laser flash photolysis (λexc = 266 nm) of (S)-FBP and (S)-FBP/HSA at 
different molar ratios. Normalised decays monitored at 360 nm. The concentration of 
(S)-FBP was 2.5·10-5 M in all cases. 
Figure 2. Laser flash photolysis (λexc = 266 nm) of (S)-FBP and (S)-FBP/BSA at 
different molar ratios. Normalised decays monitored at 360 nm. The concentration of 
(S)-FBP was 2.5·10-5 M in all cases. 
Figure 3. A. Percentage of free, site I- and site II-bound (S)-FBP in the presence of 
HSA at different [(S)-FBP]/[HSA] ratios. B. Percentage of free, site I- and site II-bound 
(S)-FBP in the presence of BSA at different [(S)-FBP]/[BSA] ratios. 
Figure 4. Laser flash photolysis (λexc = 266 nm) of (R)-FBP and (R)-FBP/HSA at 
different molar ratios. Normalised decays monitored at 360 nm. The concentration of 
(R)-FBP was 2.5·10-5 M in all cases. 
Figure 5. Laser flash photolysis (λexc = 266 nm) of (R)-FBP and (R)-FBP/BSA at 
different molar ratios. Normalised decays monitored at 360 nm. The concentration of 
(R)-FBP was 2.5·10-5 M in all cases. 
Figure 6. A. Percentage of free, site I- and site II-bound (R)-FBP in the presence of 
HSA at different [(R)-FBP]/[HSA] ratios. B. Percentage of free, site I- and site II-bound 
(R)-FBP in the presence of BSA at different [(R)-FBP]/[BSA] ratios. 
Figure 7. Decays monitored at 360 nm obtained upon laser flash photolysis (λexc = 266 
nm 0.01 M PBS, air) of (S)-FBP/BSA, (R)-FBP/BSA, (S)-FBP/HSA and (R)-FBP/HSA 

























































































































































































































































































































































































Table 1. Rate constants of triplet quenching by oxygen for FBP free, in site I and site II. 
                                                       Microenvironment kq (O2) M-1s-1
[(S)-FBP] Solution 1.0·109
[(S)-FBP]/[HSA]a Site I 2.1·108
 Site II 9.1·107
[(R)-FBP]/[HSA]a Site I 2.0·108
 Site II 3.9·107
[(S)-FBP]/[BSA]a Site I 4.0·108
 Site II 3.4·107
[(R)-FBP]/[BSA]a Site I 1.9·108
 Site II 4.6·107
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Table 2. Percentage of free, site I- and site II-bound (S)-FBP or (R)-FBP under different 
conditions. 
 Free  
(S)-FBP (%)  
 
Site I-bound  




[(S)-FBP] 100 - - 
[(S)-FBP]/[HSA]a 0 40 60 
[(S)-FBP]/[HSA]/[(S)-IBP]b 27 65 8 
[(S)-FBP]/[HSA]/[CA]b 29 59 12 
[(S)-FBP]/[BSA]a 0 39 61 
[(S)-FBP]/[BSA]/[(S)-IBP]b 8 58 34 
[(S)-FBP]/[BSA]/[CA]b 5 57 38 
[(R)-FBP]/[HSA]a 0 30 70 
[(R)-FBP]/[HSA]/[(S)-IBP]b 22 59 19 
[(R)-FBP]/[HSA]/[CA]b 26 61 13 
[(R)-FBP]/[BSA] 0 33 67 
[(R)-FBP]/[BSA]/[(S)-IBP]b 0 56 44 
[(R)-FBP]/[BSA]/[CA]b 0 50 50 
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- Equation fit: y = y0 + Afree·e(-x/tSI)  
 tfree = 1.531 ± 0.008 s 
 (S)-FBP         
Afree = 1.528 ± 0.006; r2 = 0.999 
 
- Equation fit: y = y0 + ASI·e(-x/tSI) + ASII·e(-x/tSII)  
tSI = 11.2 ± 1.7 s; tSII = 35.9 ± 1.8 s 
 (S)-FBP/HSA 1:1.75      
ASI = 0.29 ± 0.05; ASII = 0.59 ± 0.05; r2 = 0.997 
  
- Equation fit: y = y0 + Afree·e(-x/tfree) + ASI·e(-x/tSI) + ASII·e(-x/tSII)  
tfree = 1.531 ± 0.008 s; tSI = 11.2 ± 1.7 s; tSII = 35.9 ± 1.8 s 
(S)-FBP/HSA 7.5:1    
Afree = 1.239 ± 0.013; ASI = 0.053 ± 0.008; ASII = 0.140 ± 0.004; r2 = 0.994 
(S)-FBP/HSA 5:1    
Afree = 1.02 ± 0.02; ASI = 0.09 ± 0.01; ASII = 0.221 ± 0.005; r2 = 0.993 
(S)-FBP/HSA 2.5:1    























































  R-FBP/HSA 7.5:1
  R-FBP/HSA 5:1
  R-FBP/HSA 2.5:1
  R-FBP/HSA 1:1.75
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- Equation fit: y = y0 + Afree·e(-x/tSI) 
tfree = 1.503 ± 0.005 s 
(R)-FBP          
Afree = 1.524 ± 0.003 ; r2 = 0.999 
 
- Equation fit: y = y0 + ASI·e(-x/tSI) + ASII·e(-x/tSII) 
tSI = 10.2 ± 1.3 s; tSII = 39.0 ± 1.5 s 
(R)-FBP/HSA 1:1.75       
ASI = 0.26 ± 0.03; ASII = 0.62 ± 0.03; r2 = 0.998  
 
- Equation fit: y = y0 + Afree·e(-x/tfree) + ASI·e(-x/tSI) + ASII·e(-x/tSII)  
tfree = 1.503 ± 0.005 s ; tSI = 10.2 ± 1.3 s; tSII = 39.0 ± 1.5 s 
(R)-FBP/HSA 7.5:1    
Afree = 1.10 ± 0.02; ASI = 0.082 ± 0.011; ASII = 0.185 ± 0.005; r2 = 0.991 
(R)-FBP/HSA 5:1    
Afree = 1.023 ± 0.014; ASI = 0.111 ± 0.008; ASII = 0.201 ± 0.004; r2 = 0.995 
(R)-FBP/HSA 2.5:1    
































































- Equation fit: y = y0 + Afree·e(-x/tSI)  
tfree = 1.529 ± 0.004 s  
(S)-FBP          
Afree = 1.517 ± 0.003; r2 = 0.999 
 
- Equation fit: y = y0 + ASI·e(-x/tSI) + ASII·e(-x/tSII) 
tSI = 10.8 ± 0.6 s; tSII = 86.5 ± 2.2 s 
(S)-FBP/BSA 1:1.75      
ASI = 0.37 ± 0.01; ASII = 0.581 ± 0.008; r2 = 0.994 
 
- Equation fit: y = y0 + Afree·e(-x/tfree) + ASI·e(-x/tSI) + ASII·e(-x/tSII)  
tfree = 1.529 ± 0.004 s ; tSI = 10.8 ± 0.6 s; tSII = 86.5 ± 2.2 s 
(S)-FBP/BSA 7.5:1    
Afree = 1.44 ± 0.02; ASI = 0.138 ± 0.007; ASII = 0.063 ± 0.003; r2 = 0.989 
(S)-FBP/BSA 5:1    
Afree = 1.21 ± 0.02; ASI = 0.158 ± 0.005; ASII = 0.137 ± 0.002; r2 = 0.991 
(S)-FBP/BSA 2.5:1    



































































- Equation fit: y = y0 + Afree·e(-x/tSI)  
tfree = 1.514 ± 0.002 s  
(R)-FBP   
Afree = 1.532 ± 0.004; r2 = 0.999 
 
- Equation fit: y = y0 + ASI·e(-x/tSI) + ASII·e(-x/tSII) 
tSI = 6.6 ± 0.4 s; tSII = 58.6 ± 0.9 s 
(R)-FBP/BSA 1:1.75      
ASI = 0.318 ± 0.011; ASII = 0.644 ± 0.007; r2 = 0.995 
 
- Equation fit: y = y0 + Afree·e(-x/tfree) + ASI·e(-x/tSI) + ASII·e(-x/tSII)  
tfree = 1.514 ± 0.002 s; tSI = 6.6 ± 0.4 s; tSII = 58.6 ± 0.9 s 
(R)-FBP/BSA 7.5:1    
Afree = 1.39 ± 0.02; ASI = 0.121 ± 0.007; ASII = 0.092 ± 0.002; r2 = 0.991 
(R)-FBP/BSA 5:1    
Afree = 1.21 ± 0.02; ASI = 0.124 ± 0.008; ASII = 0.214 ± 0.002; r2 = 0.993 
(R)-FBP/BSA 2.5:1    
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